Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues
08 janv. 2025 07h30 HE
|
Profound Medical Corp.
– Fourth quarter revenue growth estimated at 105% to 110% year-over-year – – Company to start reporting in accordance with U.S. GAAP and filing with the SEC on U.S. domestic forms – – Profound...
Profound Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 08h15 HE
|
Profound Medical Corp.
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical to Unveil Next TULSA-AI® Module, ‘UA Alignment Assistant’
26 nov. 2024 07h45 HE
|
Profound Medical Corp.
TORONTO, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Profound Medical Announces Third Quarter 2024 Financial Results
07 nov. 2024 16h05 HE
|
Profound Medical Corp.
TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Avricore Health Recognized in Deloitte’s 2024 Technology Fast 50™ Companies to Watch
06 nov. 2024 15h14 HE
|
Avricore Health Inc.
Avricore earned 8th spot in Deloitte Canada’s 2024 Technology Fast 50™ Companies-to-Watch list, reflecting its significant growth.
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
04 nov. 2024 06h55 HE
|
Profound Medical Corp.
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective...